Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Bone Biologics (BBLGW) Research & Development (2016 - 2017)

Bone Biologics (BBLGW) has disclosed Research & Development for 2 consecutive years, with $345143.0 as the latest value for Q4 2017.

  • Quarterly Research & Development fell 50.51% to $345143.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2017, down 86.13% year-over-year, with the annual reading at $1.1 million for FY2025, 50.23% down from the prior year.
  • Research & Development for Q4 2017 was $345143.0 at Bone Biologics, up from $234264.0 in the prior quarter.
  • The five-year high for Research & Development was $4.7 million in Q1 2016, with the low at $234264.0 in Q3 2017.